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ABSTRACT
OBJECTIVE: To analyze the access to and use of medicines for high blood pressure among the 
Brazilian population according to social and demographic conditions.
METHODS: Analysis of data from Pesquisa Nacional Sobre Acesso, Utilização e Promoção do 
Uso Racional de Medicamentos (PNAUM – National Survey on Access, Use and Promotion of 
Rational Use of Medicines), a nationwide cross-sectional, population-based study, with probability 
sampling, carried out between September 2013 and February 2014 in urban households in the 
five Brazilian regions. The study evaluated the access and use of medicines to treat people with 
high blood pressure. The independent variables were gender, age, socioeconomic status and 
Brazilian region. The study also described the most commonly used drugs and the percentage 
of people treated with one, two, three or more drugs. Point estimations and confidence intervals 
were calculated considering the sample weights and sample complex plan.
RESULTS: Prevalence of high blood pressure was 23.7% (95%CI 22.8–24.6). Regarding people 
with this condition, 93.8% (95%CI 92.8–94.8) had indication for drug therapy and, of those, 94.6% 
(95%CI 93.5–95.5) were using the medication at the time of interview. Full access to medicines was 
97.9% (95%CI 97.3–98.4); partial access, 1.9% (95%CI 1.4–2.4); and no access, 0.2% (95%CI 0.1–0.4). 
The medication used to treat high blood pressure, 56.0% (95%CI 52.6–59.2) were obtained from SUS 
(Brazilian Unified Health System), 16.0% (95%CI 14.3–17.9) from Popular Pharmacy Program, 25.7% 
(95%CI 23.4–28.2) were paid for by the patients themselves and 2.3% (95%CI 1.8–2.9) were obtained from 
other locations. The five most commonly used drugs were, in descending order, hydrochlorothiazide, 
losartan, captopril, enalapril and atenolol. Of the total number of patients on treatment, 36.1% (95%CI 
34.1–37.1) were using two medicines and 13.5% (95%CI 12.3–14.9) used three or more.
CONCLUSIONS: Access to medicines for the treatment of high blood pressure may be 
considered high and many of them are available free of charge. The most commonly used drugs are 
among those recommended as first-line treatment for high blood pressure control. The percentage 
of people using more than one drug seems to follow the behavior observed in other countries.
DESCRIPTORS: Antihypertensive Agents, supply & distribution. Drug Utilization. Drugs of 
Continuous Use. Health Services Accessibility. Socioeconomic Factors. Health Surveys. 
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INTRODUCTION
Non-communicable diseases (NCD) are a global health problem and have influenced 
worldwide initiatives aimed to their control and reduction1. In Brazil, NCD represent a 
high percentage of diseases, accounting for much of the mortality and the higher cost of 
hospitalizations, especially among older adults21.
Schmidt et al.31 report that despite the increase in crude mortality rates in recent years, 
age-specific mortality rates have decreased. According to the author, this was due to the 
success of a number of public policies to reduce tobacco use and expand access to basic 
health care. Prominent among these public policies are Plano de Reorganização da Atenção 
ao Diabetes e Hipertensãoa (Plan for the Reorganization of Care for Arterial Hypertension and 
Diabetes Mellitus, Política Nacional de Medicamentos18 (National Medicine Policy), Política 
Nacional de Assistência Farmacêuticab (National Policy on Pharmaceutical Services) and 
Plano Nacional de Enfrentamento das DCNT (Brazilian Plan to Combat NCD) in Brazil for 
the period 2011-2022c.
Among NCD, high blood pressure accounts for most of the patients31. High blood pressure 
is a treatable medical condition and, if properly controlled, can delay or even prevent the 
development of symptomatic cardiovascular disease23. Medications play an important 
therapeutic role in hypertension care, both for their low cost in the early stages of the disease 
and for adherence to treatment, which, up to now, has been higher than adherence to lifestyle 
changes12. The global scenario of NCD led the World Health Organization to launch, in 2012, 
the challenge to reduce mortality from these diseases by 25.0% by 20522. The WHO considered 
access to medicines an essential component in achieving this goal2,6.
In Brazil, basic health care policies, including the expansion of free access to drugs, are 
considered examples of public initiatives3 and control of NCD. The objective of this study was 
to analyze the access to and use of medicines for high blood pressure among the Brazilian 
population, according to social and demographic conditions.
METHODS
The data for this analysis is taken from PNAUM (National Survey on Access, Use and 
Promotion of Rational Use of Medicines), a cross-sectional, population-based study. The 
study population of PNAUM consisted of people living in permanent private households in 
urban areas of the five Brazilian regions. The study analyzed data of people aged 20 or older. 
The questionnaires were answered directly by the person or by a caregiver, when they were 
unable to communicate or provide information on diseases and medicines used.
The sampling plan was complex and resulted in a probability sampling of the Brazilian 
population residing in urban areas of Brazil. Information on the sample, sampling procedures 
and other methodological procedures of PNAUM, including instruments used in the 
interview, field operation aspects and specificities of data collection are available in the 
PNAUM methodological article17.
The use of medicines to treat high blood pressure was investigated based on the following 
questions: “Has a doctor ever said you have hypertension or high blood pressure?”; “Do you 
have any medical indication to take any kind of medicine for high blood pressure?”; “Are you 
taking any of those medicines?”. Later, they were asked about the drugs being used for high 
blood pressure and detailed information on source and payment, among others aspects. 
Whenever possible, the drug names were copied from the packaging. When no packaging 
was available, the names declared by the interviewees were recorded.
The sociodemographic characteristics analyzed were: gender, age group (in two distinct 
variables: 20-39, 40-59 and 60 or over, and 20-59 and 60 or over), economic status according 
to Associação Brasileira de Empresas de Pesquisa (ABEP – Brazilian Association of Survey 
a Ministério da Saúde, 
Secretaria de Políticas de 
Saúde, Departamento de Ações 
Programáticas Estratégicas. Plano 
de reorganização da atenção à 
hipertensão arterial e ao diabetes 
mellitus. Brasília (DF); 2001. 
(Série C. Projetos, Programas e 
Relatórios, 59). Available from: 
http://bvsms.saude.gov.br/bvs/
publicacoes/miolo2002.pdf
b Ministério da Saúde, Conselho 
Nacional de Saúde. Resolução 
nº 338 de 6 de maio de 2004. 
Aprova a Política Nacional 
de Assistência Farmacêutica. 
Brasília (DF); 2004. Available 
from: http://bvsms.saude.gov.
br/bvs/saudelegis/cns/2004/
res0338_06_05_2004.html
c Ministério da Saúde, Secretaria 
de Vigilância em Saúde, 
Departamento de Análise de 
Situação de Saúde. Plano de ações 
estratégicas para o enfrentamento 
das doenças crônicas não 
transmissíveis (DCNT) no Brasil 
2011-2022. Brasília (DF); 2011. 
(Série B. Textos Básicos de Saúde). 
Available from: http://bvsms.saude.
gov.br/bvs/publicacoes/plano_
acoes_enfrent_dcnt_2011.pdf
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Companies)d (A/B, C, D/E) and Brazilian region (North, Northeast, Southeast, South, 
Midwest). The denominator in calculating prevalence of use was the total number of people 
aged 20 or over in the sample, with 95% confidence intervals (95%CI).
The access to medicines was classified as full, partial or no access. Full access was the 
situation in which people had all medicines needed to care for the disease in the last 
30 days; partial, when any medicine was missing due to financial difficulty or unavailability 
at the Unified Health System (SUS); and no access, when no drugs were obtained in the last 
30 days, also due to financial difficulty or unavailability at SUS. The denominator comprised 
people with medical indication to treat high blood pressure with drugs, excluding cases 
of intentional abandonment of treatment. Abandonment was defined as cases in which, 
despite medical indication, people were not using medications for high blood pressure; and 
cases in which they declared to be using the drugs, but had been without in the last 30 days. 
In both situations, abandonment cases were restricted to lack of medicines for reasons other 
than financial difficulty or unavailability at SUS.
Reported medicines for high blood pressure were classified into four groups, according 
to the reported use for treating high blood pressure. Group 1 consisted of drugs definitely 
used for high blood pressure, such as diuretics, angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers. Group 2 included drugs associated with patients’ care 
with high blood pressure, such as statins and acetylsalicylic acid. Group 3 corresponded to 
medicines unrelated to high blood pressure treatment, but reported by respondents as used 
for that disease. Group 4 comprised all teas or other supplements not classified as medicines. 
This classification was based on high blood pressure treatment guidelines and a review of 
the literature for some controversial cases in group 2.
The overall results of this analysis include all medications. The drugs analysis relates 
exclusively to drugs specifically used for high blood pressure treatment (group 1).
In the analysis of drugs used for high blood pressure treatment, fixed-dose combinations 
were broken down into isolated drugs. For example, for people who used a medicine with 
a fixed combination of hydrochlorothiazide and amiloride, each one of those drugs was 
analyzed separately in the evaluations that considered the number of specific drugs for the 
treatment of high blood pressure.
Pearson’s Chi-square test was used for percentage bivariate comparison, considering p < 0.05 
as significant values.
This study was approved by the Comissão Nacional de Ética em Pesquisa (CONEP – National 
Research Ethics Commission) and is registered under number 18947013.6.0000.0008. All 
interviews were conducted after the respondents or their legal representatives had read 
and signed the consent form.
RESULTS
Prevalence of self-reported high blood pressure in Brazil was 23.7% (95%CI 22.8–24.6), ranging 
from 16.3% in the North region to 26.0% in the Southeast region. In the 20-39 age group, 
prevalence was 6.0%, reaching 59.0% in the 60 or over group (Table 1).
Of the total number of people who reported high blood pressure, 93.8% affirmed having 
medical indication to treat the disease with medication. This indication ranged from 78.0% 
in the 20-39 age group to 98.1% in the group aged 60 or over (Table 1).
Among people who reported having indication for drug therapy, 94.6% were using the 
medication at the time of the interview. Use of medication increased with age. Among 
Brazilian regions, the North and Northeast regions had the lowest frequency of drug use, 
while the South and Southeast regions had the highest frequency of use (Table 1).
d Associação Brasileira de 
Empresas de Pesquisa. Critério de 
Classificação Econômica Brasil 
2013. São Paulo (SP): ABEP; 
2013. Available from: http://www.
abep.org/criterio-brasil
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Full access to medicines for high blood pressure care was higher in the South region and 
lower in the Midwest and Northeast regions. Partial access, i.e., lack of part of the drugs 
in the previous 30 days, was higher in the Midwest region and lower in the South region. 
Prevalence of access to all necessary medicines for high blood pressure care was similar 
between the different economic classes. Failure to obtain any hypertension medication for 
financial difficulties or unavailability at SUS was very low throughout the country, with minor, 
non-significant differences between the age groups (Table 2). Intentional abandonment of 
treatment reached 10.6% of cases.
Table 1. Prevalence of self-reported high blood pressure, indication of treatment and use of medication for high blood pressure among the 
Brazilian population aged 20 or over, according to sociodemographic characteristics, PNAUM, Brazil, 2104a.
Variable
Prevalence of hypertension
Hypertension patients with 
indication for drug treatment
Hypertension patients with 
indication for drug treatment 
using medication p
% 95%CI p % 95%CI p % 95%CI
Gender
Male 18.5 17.4–19.8 93.1 91.2–94.6 93.4 91.5–94.9
Female 28.1 27.0–29.1 < 0.001 94.1 92.9–95.1 0.292 95.2 94.2–96.1 0.026
Age group
20 to 39 6.0 5.2–6.9 78.0 71.1–83.6 78.4 70.8–84.5
40 to 59 27.5 26.3–28.8 93.4 91.9–94.7 94.7 93.4–95.8
60 or over 59.0 57.4–60.5 < 0.001 98.1 97.6–98.5 < 0.001 97.6 97.0–98.1 < 0.001
Brazilian region
North 16.3 14.6–18.1 91.7 89.0–93.9 91.4 88.1–93.8
Northeast 21.7 20.3–23.1 92.2 90.0–93.9 91.1 87.6–93.7
Southeast 26.0 24.3–27.7 94.9 93.0–96.2 95.6 94.2–96.7
South 22.4 20.8–24.0 93.0 90.4–95.0 97.4 96.1–98.2
Midwest 24.1 22.0–26.3 < 0.001 92.9 90.4–94.8 0.495 94.0 92.2–95.5 < 0.001
CCEBb
A/B 22.3 20.4–24.3 94.7 92.6–96.2 96.2 94.3–97.5
C 23.9 22.8–25.0 93.4 91.9–94.7 94.8 93.6–95.8
D/E 24.7 23.1–26.3 0.127 93.5 91.5–95.1 0.064 92.3 89.2–94.6 0.019
Total 23.7 22.8–24.6 93.7 92.6–94.7 94.6 93.5–95.5
a Percentage adjusted by sample weights and post-stratification according to age and gender.
b Classified according to Critério de Classificação Econômica Brasil 2013 (CCEB 2013 – Brazilian Economic Classification Criterion) of Associação 
Brasileira de Empresas de Pesquisa (ABEP – Brazilian Association of Survey Companies). Available from: http://www.abep.org
Table 2. Access to high blood pressure medication by hypertension patients with medical indication for drug treatment by age, gender, ABEP 
and Brazilian region. PNAUM, Brazil, 2104a.
Variable
Full accessb Partial accessc No accessd
p
% 95CI% % 95CI% % 95CI%
Gender
Male 98.6 97.8–99.0 1.3 0.9–2.0 0.1 0.0–0.3
Female 97.6 96.8–98.2 2.2 1.6–3.0 0.3 0.1–0.5 0.046
Age group
20 to 59 97.2 96.1–97.9 2.5 1.7–3.5 0.4 0.2–0.7
60 or over 98.6 98.0–99.1 1.3 0.9–1.9 0.05 0.0–0.1 0.001
Brazilian region
North 97.1 93.6–98.7 2.5 1.0–6.2 0.3 0.2–0.7
Northeast 96.1 94.4–97.2 3.3 2.2–4.9 0.6 0.3–1.4
Southeast 98.7 97.7–99.2 1.3 0.7–2.2 0.1 0.0–0.4
South 99.2 98.3–99.6 0.7 0.3–1.6 0.1 0.0–0.5
Midwest 95.7 93.8–97.0 4.0 2.7–5.8 0.4 0.1–1.1 < 0.001
CCEBe
A/B 98.6 97.6–99.2 1.0 0.5–2.0 0.4 0.1–1.2
C 97.7 96.8–98.3 2.2 1.6–3.0 0.1 0.1–0.3
D/E 97.7 96.6–98.5 2.0 1.3–3.2 0.3 0.1–0.6 0.103
Total 97.9 97.3–98.4 1.9 1.4–2.4 0.2 0.1–0.4
a Percentage adjusted by sample weights and post-stratification according to age and gender.
b Full access: provision of all necessary medicines to treat hypertension in the previous 30 days, either free of charge or paid for by patients.
c Lack of any medicine to treat hypertension in the previous 30 days due to financial difficulties or unavailability at SUS (Brazilian Unified Health System).
d No access due to financial difficulties or unavailability at SUS.
e Classified according to Critério de Classificação Econômica Brasil 2013 (CCEB 2013 – Brazilian Economic Classification Criterion) of Associação 
Brasileira de Empresas de Pesquisa (ABEP – Brazilian Association of Survey Companies). Available from: http://www.abep.org
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Of all the medicines reported for use in high blood pressure, group 1 (medicines definitely 
used to treat high blood pressure) corresponded to 90.5%, group 2 (drugs associated with 
high blood pressure treatment), to 4.1%, group 3 (drugs not indicated for high blood pressure), 
to 3.2%, and group 4 (supplements and herbs), to 2.3%. Of medicines used specifically to treat 
high blood pressure (group 1), 92.4% were single-drug and 7.6% were fixed-dose combinations, 
the most common being hydrochlorothiazide combined with losartan or atenolol or 
amiloride. Separately, the most common specific drugs used to treat high blood pressure 
were, in descending order: hydrochlorothiazide, losartan, captopril, enalapril, amlodipine 
and atenolol, which corresponded to approximately 81.0% of all reported drugs (Table 3).
Among respondents treated with specific drugs for hypertension, 49.9% used only one drug, 
36.1% used two, and 13.5% used three or more drugs (Table 4). High blood pressure treatment 
with more than one drug increased with age. In the 20 to 39 age group, 43.3% of hypertensive 
patients used more than one drug, while for those over 60 the figure was 52.2%. Differences 
were also observed among individuals suffering only from high blood pressure. Of those, 
46.0% treated hypertension with more than one drug, and among people with two or more 
other chronic diseases, 55.8% used more than one drug. In the North region, the use of two 
or more drugs was lower than that observed in the other Brazilian regions.
Table 3. Most commonly used medicines to treat high blood pressure, regardless of fixed-dose 
combinations or number of drugs used. PNAUM, Brazil, 2014*.
Drug % 95CI% cumulative %
Hydrochlorothiazide 23.9 22.7–25.1 23.9
Losartan 20.1 19.0–21.3 44.0
Captopril 11.2 10.2–12.2 55.2
Enalapril 10.5 9.4–11.7 65.7
Atenolol 9.0 8.2–9.9 74.6
Amlodipine 6.0 5.4–6.6 80.6
Propranolol 4.1 3.6–4.7 84.7
Furosemide 2.4 2.0–2.8 87.1
Nifedipine 1.8 1.5–2.2 88.9
Chlorthalidone 1.8 1.4–2.2 90.7
Other hypertension drugs 9.3 8.4–10.3 100
* Percentage adjusted by sample weights and post-stratification according to age and gender.
Table 4. Percentage of number of drugs, regardless of fixed-dose combinations, used to treat high blood pressure (HBP) per age group, 
number of chronic diseases and Brazilian region. PNAUM, Brazil, 2014*.
Variable One drug 95CI% Two drugs 95CI% Three or more drugs 95CI% p
Gender
Male 52.4 46.9–55.2 35.5 32.9–38.2 12.0 10.3–14.0
0.034
Female 48.5 46.6–50.5 37.2 35.4–39.0 14.3 12.9–15.9
Age group
20 to 39 56.7 49.0–64.1 33.1 25.6–41.5 10.2 5.9–17.0
0.06140 to 59 51.1 48.2–49.8 36.9 34.1–39.8 12.0 10.3–13.8
60 or over 47.8 45.9–49.8 36.9 35.1–38.7 15.3 13.7–17.0
Number of 
chronic diseases
HBP only 54.0 51.3–56.6 36.3 34.0–38.6 9.8 8.0–11.9
0.001
HBP and another chronic 
disease
51.8 48.8–54.9 35.4 32.5–38.4 12.8 10.9–14.9
HBP and two or more other 
chronic diseases
44.1 41.5–46.9 37.8 35.5–40.3 18.0 15.9–20.2
Brazilian region
North 71.9 68.6–75.0 24.7 22.0–27.6 3.4 2.6–4.6
0.001
Northeast 48.7 45.7–51.6 38.6 35.6–41.5 12.7 10.8–14.8
Southeast 48.5 46.0–51.1 36.9 34.6–39.3 14.6 12.6–16.9
South 51.7 48.0–55.3 35.8 32.9–38.8 12.5 10.7–14.5
Midwest 47.5 43.7–51.3 37.1 33.9–40.4 15.5 13.1–18.1
Total 49.9 48.3–51.5 36.1 34.1–37.1 13.5 12.3–14.9
* Percentage adjusted by sample weights and post-stratification according to age and gender.
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Of medicines used to treat high blood pressure, 56.0% were obtained from SUS, 16.0% 
from Programa Farmácia Popular (program-specific or accredited drugstores) and 2.3% 
elsewhere. Payment by the actual patients corresponded to 25.7% of medications used to 
treat this condition.
DISCUSSION
Prevalence of self-reported high blood pressure in this study was 23.7% for all ages, 18.5 in 
men and 28.1 in women. Barros et al.5, analyzing data from the 2008 Pesquisa Nacional por 
Amostra de Domicílios (PNAD – National Household Sample Survey), found a prevalence 
of 11.3% for men, 16.5% for women and 14.0% for both genders and all ages. In a summary 
measure of several studies, Schmidt et al.31 found a 17.3% prevalence for men and women 
over 20. Among men, the prevalence of 19.2% was slightly higher than in the 2008 survey, 
when it was estimated at 17.3% (95%CI 17.0–17.6%). In the VIGITEL telephone surveye for 
all 27 cities, considering adults (aged over 18), prevalence was 24.1%, with a higher rate of 
high blood pressure among women (26.3%) than men (21.5 %). The 2013 Pesquisa Nacional 
de Saúde (National Health Research)f showed a prevalence of self-reported hypertension of 
21.4% (95%CI 20.8–22.0) for people over 18.
When compared with previous population studies, prevalence of self-reported high blood 
pressure in this study confirms the upward trend of this disease in all age groups. The 
figures  found in the Vigitel survey are higher, probably because this tool included only state 
capitals and metropolitan areas of Brazil, where prevalence of hypertension tends to be 
higher, whether due to increased presence of risk factors, greater access to diagnosis or a 
combination of both factors.
In this study, the question on the use of medicines for high blood pressure was preceded 
by another question about the existence of medical indication for treatment of high blood 
pressure with medications. This question was included after the study identified that one of 
the reasons participants were not using drugs was the lack of medical indication.
Ferreira et al.11, analyzing data of the 2008 PNAD25, found that 17.0% of patients did not use 
high blood pressure medication. The study shows that of people with hypertension, 6.2% 
had no medical indication to treat the disease with medication, and only 5.4% of those with 
indication were not using the drugs. The difference in the results of both studies may be 
due the authors assuming that all patients with high blood pressure should use medicines 
to treat the condition.
Indication for treatment with medication is high. This may reflect late diagnosis, given that in 
stage 1 hypertension, lifestyle change is the first indication, with drug treatment only introduced 
six months after that measure failsg. When diagnosis is delayed, greater severity of the disease 
or less success in the use of non-drug treatment is expected, due to lack of lifestyle changes. 
A further aspect is the behavior of doctors, who, expecting that patients will not adhere to 
non-drug treatment, introduce drug treatment alongside lifestyle change recommendations.
Analysis of PNADh data showed a significant difference in drug use between men and women, 
with lower rates among men. Data from this study show a slightly lower use among men 
compared to women and this difference was not significant.
Also consistent are the lower rates of medicine use among younger age groups. This study 
shows that younger people receive less indication for drug treatment, and when they do, 
adherence is very low compared to older people. Consequently, young people miss the 
opportunity to prematurely reduce cardiovascular risks with the use of medicines and may 
experience further harm in future complications of the clinical condition.
Overall, indication and use of medications were high, which should be considered positive, 
especially because it is an asymptomatic clinical condition. However, a more accurate 
e Ministério da Saúde, Secretaria 
de Vigilância em Saúde. Vigitel 
Brasil 2013: vigilância de 
fatores de risco e proteção para 
doenças crônicas por inquérito 
telefônico. Brasília (DF); 2014. 
Available from: http://bvsms.
saude.gov.br/bvs/publicacoes/
vigitel_brasil_2013
f Instituto Brasileiro de Geografia 
e Estatística. Pesquisa Nacional 
de Saúde 2013: percepção do 
estado de saúde, estilos de vida 
e doenças crônicas - Brasil, 
Grandes Regiões e Unidades da 
Federação. Rio de Janeiro (RJ): 
IBGE; 2014. Available from: 
ftp://ftp.ibge.gov.br/PNS/2013/
pns2013.pdf
g Ministério da Saúde, 
Secretaria de Atenção à Saúde, 
Departamento de Atenção 
Básica. Estratégias para o 
cuidado da pessoa com doença 
crônica: hipertensão arterial 
sistêmica. Brasília (DF); 2013. 
(Cadernos de Atenção Básica, 
37). Available from: http://bvsms.
saude.gov.br/bvs/publicacoes/
estrategias_cuidado_pessoa_
doenca_cronica.pdf
h Instituto Brasileiro de 
Geografia e Estatística. Pesquisa 
Nacional por Amostra de 
Domicílios - PNAD. Rio de 
Janeiro (RJ): IBGE; 2008. 
Available from: http://www.
ibge.gov.br/home/estatistica/
populacao/trabalhoerendimento/
pnad2008/
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assessment of treatment adequacy and follow-up is needed as a next step in the care of 
hypertension. Evidence shows that inadequate understanding of the nature of hypertension 
leads to discontinuation of treatment when blood pressure levels are normalized. Other 
causes for temporary interruption or undertreatment of the disease are the occurrence of 
side effects, forgetfulness, or reasons related to health services, such as organization and 
structure, sometimes involving the relationship between doctor and patient2,9.
Nationwide data on access to medicines are still scarce, especially at the household level. 
Paniz et al.19, studying users in the program Estratégia de Saúde da Família (Family Health 
Strategy) in 41 municipalities in the South and Northeast regions in 2005, found that 81.2% 
had full access, albeit with regional differences, rates being higher in the South. Increased age, 
better socioeconomic status and higher education level were factors associated with greater 
access. In one state capital in southern Brazil, access was 95.8%5. Among the population 
covered by the Programa de Saúde da Família (Family Health Program) in another state 
capital in southern Brazil, overall access to medicines was also 95.0%8. Those studies show 
high access to medicines for high blood pressure, and, on average, half of the medications 
was obtained free of charge from SUS. This study shows an increase in drugs obtained from 
the SUS basic network, as well as from the Farmácia Popular (Popular Pharmacy Program), 
which accounted for 16.0% of medicines used in hypertension care.
Most part of the medicines used in hypertension care is available for free, whether from the 
SUS network or drugstores accredited by the program Aqui Tem Farmácia Popular (Popular 
Pharmacy Here). Thus, almost three out of four medicines used in high blood pressure care 
were funded by SUS.
Of the 10 drugs most commonly used to treat hypertension, only chlorthalidone did not 
feature in Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential 
Medicines) for 2013i. Of those 10 drugs, nine can be obtained from the SUS basic network and 
Popular Pharmacy Program network free of charge. Moreover, municipal lists of medications 
may include those drugs, making them available to patients through SUS in such municipalities.
The most commonly used drugs were hydrochlorothiazide, followed by losartan, captopril 
and enalapril. These results are similar to those found in other studies in which diuretics and 
renin-angiotensin system antagonists are the drugs used to treat high blood pressure13,22. 
A meta-analysis of 31 randomized controlled trials involving 190,606 participants carried out 
by the Blood Pressure Lowering Treatment Trialists’ Collaboration8 showed no significant 
differences between the various drugs used to treat high blood pressure in the prevention 
of cardiovascular events.
High blood pressure treatment with more than one drug is observed in other countries. 
In England, 45.0% of patients undertake monotherapy; 36.0%, two drugs; 14.0%, three drugs; 
and 4.0%, four drugs10. In the United States, the percentage of patients who use more than 
one drug rose from 29.1% in 1988-1994 to 35.8% in 1999-200214 and to 47.7% in 2009-201015.
In short, prevalence of high blood pressure continues to increase among the adult Brazilian 
population. Access to medicines to treat this disease proved to be quite high. Compared with 
previous studies, this increase appears to be consistent. Pharmaceutical care public policies 
may explain this phenomenon. Most of the drugs used are among those recommended in the 
literature as first-line drugs for high blood pressure treatment. In this study, the number of 
drugs used shows the same trend observed in the United States and England, i.e., a growth 
in the number of drugs needed to keep blood pressure under adequate control.
Full access to medicines for high blood pressure can be seen as the first step in the treatment 
of this clinical condition, but not the only one. About 50.0% of treated patients do not 
have adequate blood pressure control16,20. Access to drugs must be complemented by 
good adherence to treatment, appropriate management of the drugs for each patient, and 
control of other factors that may hinder blood pressure control, such as high salt intake or 
obstructive sleep apnea21.
i Ministério da Saúde, Secretaria 
de Ciência, Tecnologia e Insumos 
Estratégicos, Departamento 
de Assistência Farmacêutica e 
Insumos Estratégicos. Relação 
Nacional de Medicamentos 
Essenciais: RENAME 2013. 8 ed. 
Brasília (DF); 2013. Available 
from: http://www.sinfaerj.org.
br/Arquivos/livro_rename_
out_2013.pdf
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